Cryptophycin anticancer drugs revisited.
A recent publication reveals the biosynthetic building blocks, genetic code, and broad substrate tolerance of the enzymes of the cryptophycin biosynthetic pathway. This work lays the foundation for the production of poorly accessible yet very promising members of this family of anticancer compounds from lichen cyanobacterial symbionts. Chemoenzymatic production or precursor-directed biosynthesis might bring candidates from this family of natural products back to clinical trials.